Survival in a cohort of patients with chronic obstructive pulmonary disease: Comparison between primary and tertiary levels of care;Supervivencia en una cohorte con EPOC. Análisis comparativo entre el primer y tercer niveles de atención

Archivos de Bronconeumologia

Volumn 41, Issue 5, 2005, Pages 260-266

  Rico Mendez F G ^a   Barquera, S ^b   Mugica Hernandez J J ^a   Espinosa Perez J L ^a   Ortega, S ^a   Ochoa, L G ^a  

^a Hospital General Dr Gaudencio Gonzalez Garza   (Mexico)

^b INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

Author keywords

Copd; Mortality; Survival

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE EXACERBATION; EDUCATION PROGRAM; EXERCISE; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHYSICAL ACTIVITY; PRIMARY MEDICAL CARE; PROBABILITY; SEX RATIO; SURVIVAL;

EID: 24144478264     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13074592     Document Type: Article

References (30)

1. Hurd SS. International efforts directed at attacking the problem of COPD. Chest. 2000;117 Suppl:336-8.
2. Rico-Méndez FG, Vázquez SB, Díaz V, Barquera S, Múgica JJ. Uso y abuso de la prescripción de oxígeno domiciliario en un Centro Médico Nacional de Salud Pública de México. Rev Med IMSS. 2003;41:473-80.
3. Sullivan S, Elixhauser A, Buist S, Luce BR, Eisenberg J, Weiss K. National asthma education and prevention program. Working group report on the cost effectiveness of asthma care. Am J Respir Crit Care Med. 1996;154 Suppl:84-95.
4. Anthonisen N. Epidemiology and Lung Health Study. Eur Resp Rev. 1997;45:202-5.
5. American Thoracic Society. Standars for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Resp Dis. 1987;136:225-44.
6. Hulley S, Cummings S. Diseño de la investigación científica. Barcelona: Doyma; 1993. p. 216.
7. American Thoracic Society Statement. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis. 1991;144:1202-18.
8. Goldman HI, Beclake M. Respiratory function tests: normal values at medium altitudes and the prediction of normal results. Am Rev Tuberc. 1959;79:454-67.
9. Cotes JE, Hall AM. The transfer factors, for the lung: normal values in adults. En: Arcangeli P, editor. Normal values for respiratory function in man. Torino: Panminerva Medica; 1970. p. 327-43.
10. Ferguson GT, Cherniack R. Management of chronic obstructive pulmonary disease. N Engl J Med. 1993;328:1017-22.
11. Norman G, Streiner D. Bioestadística. Barcelona: Harcourt; 2000. p. 187-94.
12. National Heart, Lung and Blood Institute- World Health Organization Global Strategy for Diagnosis Management and Prevention of Chronic Obstructive Pulmonary Disease (GOLD). September 2000.
13. Hurd S. The impact of COPD on lung health worldwide: epidemiology and incidence. Chest. 2000;117 Suppl:1-4.
14. National Hearth Lung and Blood Institute. Morbidity and mortality: 2000 chart book on cardiovascular, lung, and blood disease. Bethesda: National Institute of Health, National Heart, Lung, and Blood Institute. 2000.
15. Rijcken B, Britoon J. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J. 1998;7:41-73.
16. Medical Research Council. Value of chemoprophylaxis for chronic bronchitis. Br Med J. 1966;1:1317-22.
17. Camargo CA. The relationship between COPD exacerbation and other outcomes. Eur Resp Rev. 2002;82:9-10.
18. Soler JJ, Sánchez M, Latorre M, Alamar J, Román P, Perpiña M. Impacto asistencial hospitalario de la EPOC. Peso específico del paciente con EPOC de alto consume sanitario. Arch Bronconeumol. 2001;37:375-81.
19. Miravitlles M, Murio C, Guerrero T. Dafne Group. Factors associated with increased risk of hospital admission in a cohort of ambulatory COPD. Eur Resp J. 2000;16 Suppl:31.
20. Informe Lasist. Impacto en estancias por diferencias de estancias medias. Valencia: Conselleria de Sanitat i Consum. Generalitat Valenciana; 1998.
21. Connors AF, Dawson NV, Thomas C, Harell FE, Desbiens N, Fulkerson WJ. Outcomes following acute exacerbation of severe chronic obstructive lung disease: The SUPPORT Investigation. Am J Respir Crit Care Med. 1996;154:959-67.
22. Zielinski J, MacNee W, Wedzicha J. Causes of death in patient with COPD and chronic respiratory failure. Monaldi Arch Chest. 1997;52:43-7.
23. Almagro P, Calbo E, Ochoa de Echegüen A, Barreiroi B, Quintana S, Heredia JL. Mortality after hospitalization for COPD. Chest. 2002;121:1441-8.
24. Fernández Pérez ML, Otero GI, Blanco M, Montera MC, Valiño P, Hernández V. Comorbilidad y mortalidad en pacientes con EPOC. XXXIV Congreso Nacional de la Sociedad Española de Neumología y Cirugía Torácica. La Coruña, España. Junio 2001. Arch Bronconeumol. 2001;37 Supl 1:10-1.
25. Peto R, López A, Boreham J, Thun M, Heath C. Mortality from tobacco in development countries: indirect estimation from national vital statistic. Lancet. 1992;339:1268-78.
26. Murray C, López A. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349:1498-504.
27. Grupo de Trabajo de la SEPAR. Normativa sobre rehabilitación respiratoria. Arch Bronconeumol. 2000;36:257-74.
28. Mayo P, Richman J, Harris W. Results of a program to reduce admission for adult asthma. Ann Intern Med. 1990;112:864-71.
29. Sans-Torres J, Domingo C, Solá J, Marín A. Efectividad de una consulta monográfica para pacientes con EPOC evolucionado. Arch Bronconeumol. 2001;37:14.
30. Antoñana JM, Sobradillo V, De Marcos D, Chic JB, Galdiz JB, Iriberri M. Programa de altas précoces y asistencia domiciliaria en pacientes con exacerbación de enfermedad pulmonar obstructiva crónica y asma bronquial. Arch Bronconeumol. 2001;37: 489-94.